CELC · CIK 1603454
What Celcuity Inc. told the SEC could break it.
1 self-disclosed vulnerability, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
A limited set so far, we surface every cited disclosure we’ve extracted for CELC. More may follow as additional filings are processed.
In its own words
What could break it.
Other disclosures
- Full reliance on third-party CMOs to make/formulate gedatolisib (lead product) for clinical & commercial supplymedium
Celcuity owns no manufacturing capability for its lead (and only therapeutic) product gedatolisib, which is entering commercial launch (NDA accepted, PDUFA target July 17, 2026). It relies entirely on third parties to formulate, manufacture and distribute the drug, having contracted with contract manufacturing organizations (CMOs) to produce the drug substance and to formulate, produce and package finished drug product for clinical use and, if approved, commercial use. Any CMO capacity, quality, or supply interruption would directly impair its ability to run trials and to launch and supply gedatolisib.
“We rely on third parties to formulate, manufacture and distribute gedatolisib. We have entered into agreements with contract manufacturing organizations (“CMOs”) to produce the drug substance gedatolisib and formulate, produce and package finished drug product for clinical use and, if approved, commercial use.”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its suppliers
“We paid Pfizer a $5.0 million upfront fee upon execution of the Gedatolisib License Agreement and issued 349,406 shares of our common stock to Pfizer pursuant to an Equity Grant Agreement.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch